Pulmonary drug delivery systems of antibiotics for the treatment of respiratory tract infections

Abstract

Respiratory infections cause an extensive health problem in the world. The common treatment for respiratory infections is the administration of antibiotics orally or parenterally in a high dose. Unfortunately, these therapies of high-dose antimicrobials have many disadvantages, such as severe side effects. Consequently, the development of an inhaled formulation provides the delivery of the therapeutic dose of the drug to the organ of interest without overt systemic effects. Novel technological advances have led to the development of inhaled antibiotics. Recent particle engineering techniques for dry powder inhalers (DPI) or mesh nebulizers have higher aerosolization efficiencies and promote the delivery of high-dose antibiotics to the lungs. However, advanced formulation strategies are in high demand for the development of new formulations for more types of antibiotics. Despite all the current research, patient compliance with pulmonary dosage forms remains to be very low because of the inappropriate administration techniques. Hence, this review focuses on three key aspects of the pulmonary dosage forms of antibiotics; the marketed products, the formulation approaches under research and innovative formulation strategies for achieving drug delivery through the respiratory tract.

Modern World Applications for Nano-Bio Materials: Tissue Engineering and COVID-19

“…Drug delivery systems suitable for IR development must consider some characteristics of the particles such as density, charge, shape and diameter, solubility, and hygroscopicity. Moreover, certain factors regarding the patient's respiratory system as airflow velocity and airway structure (Pannonhalminé Csóka et al, 2019). However, despite the complexity of this pathway, the IR is attractive for several pulmonary diseases, where the speed reaction and focal delivery are crucial.…”

Development of Inhalable Chitosan nano system conjugated with Hyaluronic acid for treatment of Tuberculosis

“…Dry powder inhalers (DPI) comprised of biodegradable polymeric nanocarriers with adequate aerodynamic profile, drug release and biocompatibility is a major challenge for pulmonary drug delivery. Quality by design approach was therefore employed to critically evaluate the risk assessment profile to enhance the product optimization [2]. Physicochemical tests including FT-IR, DSC, TGA, XRPD, SEM, size analyses and aerodynamic characterization provided useful data about compatibility and stability of the nanoparticular system.…”

Development of novel formulated ciprofloxacin hydrochloride containing dry powder inhalation system

“…(1) on the surface of the second component (2). It is used to characterize the distribution in binary systems.…”

“…asthma, cystic fibrosis (CF), tuberculosis, etc.). In particular, the use of antibiotics [2] in inhalation therapy has a lot of potentials, as bacterial infections typical of many lung diseases can be treated locally with a remarkable reduction in systemic side effects compared to oral administration. There are not yet many inhaled products containing antibiotics on the market, but several promising formulations have been published.…”